General Toxicity Notes
May decrease renal function. Decrease platelet aggregation. Nephrotic syndrome, interstitial nephritis, hyperkalemia, sodium retention.
Half-Life (Normalesrd) Hours
1-2/Unchanged
Plasma Protein Binding %
>99
Volume Of Distribution L/Kg
0.12-0.17
Dose For Normal Renal Function
25-75 mg bid
Adjustment For Renal Failure Method
D
Adjustment For Renal Failure Gfr, Ml/Min >50 [Recommended Level]
50-100% [D]
Adjustment For Renal Failure Gfr, Ml/Min 10-50 [Recommended Level]
25-50% [D]
Adjustment For Renal Failure Gfr, Ml/Min <10 [Recommended Level]
25% [D]
Supplement For Dialysis [Recommendation Level]: Ihd
IHD: None, [D]
Supplement For Dialysis [Recommendation Level]: Pd
PD: None, [D]
Supplement For Dialysis [Recommendation Level]: Crrt
CRRT: Not applicable
References
Cunningham RF, Israili ZH, Dayton PG. Clinical pharmacokinetics of probenecid. Clin Pharmacokinet. 1981; 6: 135-51. [PMID: 7011657] / Dayton PG, Perel JM. The metabolism of probenecid in man. Ann N Y Acad Sci. 1971; 179: 399-402. [PMID: 5285384]